NorthWest Biotherapeutics Inc (NWBO)

[Single Stock]

BMS finds no advantage for Opdivo + Yervoy compared to AZ’s Imfinzi in NSCLC
(GBI News)
Bristol-Myers Squibb (BMS; NYSE: BMY) last week revealed that a late-stage trial for checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) in unresectable stage III non-small cell lung cancer (NSCLC) did not meet its primary endpoint of progression-free survival (PFS). The study evaluated Opdivo plus concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy in comparison with a regimen of CCRT followed by durvalumab (AstraZeneca’s (AZ; NASDAQ: AZN) anti-PD-L1 drug Imfinzi).
The company announced plans to publish complete results after concluding a full evaluation of the data, and noted that the combination’s safety profile was consistent with that of each component.
According to the press release, Opdivo combinations are approved in certain settings of resectable or metastatic NSCLC.